Progressive Supranuclear Palsy Epidemiology Summary

• Progressive supranuclear palsy is a rare neurological disorder that affects body movements, walking and balance, and eye movements. Progressive Supranuclear Palsy is caused by damage to nerve cells in areas of the brain that control thinking and body movements.
• Progressive Supranuclear Palsy comprises several phenotype variants; Richardson’s syndrome is the most common phenotype of Progressive Supranuclear Palsy. Other phenotypes include Progressive Supranuclear Palsy-Parkinsonism, Progressive Supranuclear Palsy with a predominant frontal presentation, Progressive Supranuclear Palsy with a corticobasal syndrome, and others.
• Among the 7MM, the United States has captured the highest number of Progressive Supranuclear Palsy-diagnosed prevalent cases in 2025.
• Among all the phenotype-specific cases of Progressive Supranuclear Palsy, Richardson’s syndrome accounted for more than 50% of cases in 2025.
• The rising burden of Progressive Supranuclear Palsy may be attributed to demographic aging, enhanced recognition of atypical parkinsonian syndromes, improved neuroimaging and biomarker development enabling earlier diagnosis, and a greater understanding of the role of tau protein aggregation and neurodegeneration in disease pathogenesis.
• Diagnosing Progressive Supranuclear Palsy is difficult due to symptom overlap with other movement disorders. It relies on identifying key symptoms, clinical examination, and ruling out other causes, with MRI sometimes helping by showing characteristic brain atrophy.

DelveInsight’s “Progressive Supranuclear Palsy Epidemiology, Forecast – 2036” report delivers an in-depth understanding of Progressive Supranuclear Palsy, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Progressive Supranuclear Palsy Understanding and Treatment Algorithm

Progressive Supranuclear Palsy Overview and Diagnosis

Progressive supranuclear palsy, also known as Steele-Richardson-Olszewski, is a rare neurodegenerative disorder. It belongs to a group of diseases called tauopathies. The exact cause of Progressive Supranuclear Palsy is unknown. However, it is believed to involve the abnormal accumulation of tau protein in certain areas of the brain, particularly the basal ganglia and brainstem, forming abnormal tangles, leading to the degeneration of brain cells. It typically begins around the age of 60, and the symptoms gradually worsen over time. It is often characterized by the gradual deterioration of movement, balance, and coordination, dysphagia, impairment of cognitive functions, control of eye movements, and others. The most frequent comorbidities observed in Progressive Supranuclear Palsy patients are nervous system disorders, connective tissue diseases, eye disorders, and non-traumatic joint disorders.

Diagnosis of Progressive Supranuclear Palsy remains primarily clinical, as no definitive diagnostic tests or brain imaging techniques are currently available. Physicians typically assess medical history and conduct comprehensive physical and neurological examinations to evaluate characteristic features of the disease. Early identification of abnormalities in gait, eye movements, speech, and swallowing is crucial for differentiating Progressive Supranuclear Palsy from other neurodegenerative disorders. Although not diagnostic, magnetic resonance imaging (MRI) may reveal atrophy of the upper brainstem and assist in evaluating structural brain changes associated with Progressive Supranuclear Palsy.

Further details related to country-based variations are provided in the report...

Progressive supranuclear palsy Epidemiology

Key Findings from Progressive Supranuclear Palsy Epidemiological Analysis and Forecast

• According to a recent study, it is reported that the prevalence of Progressive Supranuclear Palsy ranges from 5.8 to 6.5 per 100,000 people.
• The National Organization for Rare Disorders (NORD) estimates that Progressive Supranuclear Palsy affects at least 20,000 individuals in the US. Some reports suggest a prevalence of 5 to 17 cases per 100,000 people, while recent autopsy studies have identified Progressive Supranuclear Palsy pathology in 2–6% of elderly individuals who had not been diagnosed with the condition before death.
• As per secondary research, the prevalence of Progressive Supranuclear Palsy in Japan is estimated at 0.7–3.0 cases per 10,000 population based on four studies using standard case ascertainment methods.
• According to the Progressive Supranuclear Palsy Association UK, it is estimated that approximately 4,000 people are living with Progressive Supranuclear Palsy in the UK.

Scope of the Progressive Supranuclear Palsy Epidemiology  Report

• The report covers a segment of key events, an executive summary, a descriptive overview of Progressive Supranuclear Palsy, explaining its causes, signs, symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Progressive Supranuclear Palsy Epidemiology Report Insights

• Progressive Supranuclear Palsy Patient Population Forecast

Progressive Supranuclear Palsy Epidemiology Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast

Gain strategic insights with DelveInsight's Progressive Supranuclear Palsy Market Forecast, Epidemiology and Market Insights– 2036 for informed investment and business decisions.

FAQs

• What are the disease risks, burdens, and unmet needs of Progressive Supranuclear Palsy?
• What will be the growth opportunities across the 7MM concerning the patient population with Progressive Supranuclear Palsy?
• What is the Progressive Supranuclear Palsy prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What is the historical and forecasted Progressive Supranuclear Palsy patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy Progressive Supranuclear Palsy Epidemiology Report

• Insights on Progressive Supranuclear Palsy burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the Progressive Supranuclear Palsy epidemiology analysis and patient population trends.